Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Impact of plasma pTau181 levels on clinician diagnostic confidence and management in memory and cognition clinics: A multi-site before-and-after study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Analysis of second-generation epigenetic clocks reveals further associations between disproportionate biological ageing and hippocampal volume.

GeroScience·2026
Same author

Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.

EBioMedicine·2026
Same author

Evidence for direct and sleep-moderated relationships between aquaporin-4 genetic variants and Alzheimer's disease phenotypes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Genetic variation in the glymphatic pathway predicts cognition and neurodegeneration in preclinical Alzheimer's disease.

Research square·2026
Same journal

Mapping the 3D Chromosome Organization of a Biosynthetic Gene Cluster by Capture Hi-C (CHi-C).

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Mapping the 3D Chromosome Organization of Streptomyces by Hi-C.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

CUT&Tag Epigenomic Profiling of Biosynthetic Gene Clusters in Arabidopsis thaliana.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Rhizobium rhizogenes-Mediated Hairy Root Transformation Protocol for Lotus japonicus and Other Legumes.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Characterization of Bioactive Saponins from Sea Cucumbers.

Methods in molecular biology (Clifton, N.J.)·2026
Same journal

Methods for Functional Validation of Terpenoid Metabolic Clusters in Nicotiana benthamiana and Aspergillus oryzae.

Methods in molecular biology (Clifton, N.J.)·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Quantitative approaches to amyloid imaging.

Victor L Villemagne1, Graeme O'Keefe, Rachel S Mulligan

  • 1Department of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, VIC 3084, Australia. villemagne@petnm.unimelb.edu.au

Methods in Molecular Biology (Clifton, N.J.)
|December 15, 2010
PubMed
Summary
This summary is machine-generated.

Positron emission tomography (PET) with novel amyloid imaging agents aids in quantifying beta-amyloid (Aβ) brain deposition. This is crucial for diagnosing Alzheimer's disease (AD) and monitoring new therapies.

More Related Videos

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Related Experiment Videos

Last Updated: Jun 6, 2026

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
07:28

Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections

Published on: May 19, 2022

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

Area of Science:

  • Neuroimaging
  • Neurology
  • Radiochemistry

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder causing dementia, characterized by memory loss and cognitive decline.
  • Beta-amyloid (Aβ) deposition in the brain is implicated in AD pathogenesis.
  • In vivo amyloid imaging using positron emission tomography (PET) offers insights into Aβ burden.

Purpose of the Study:

  • To explore the utility of in vivo amyloid imaging for quantifying Aβ burden in the brain.
  • To facilitate research into the causes, diagnosis, and treatment of dementias, particularly AD.
  • To describe image acquisition approaches for novel amyloid imaging agents.

Main Methods:

  • Utilizing positron emission tomography (PET) for non-invasive quantification of Aβ burden.
  • Applying compartmental or graphical analyses to kinetic data for quantitative assessment.
  • Employing novel amyloid imaging agents radiolabeled with Carbon-11 ((11)C) or Fluorine-18 ((18)F).

Main Results:

  • PET imaging shows significantly higher Aβ retention in the grey matter of AD patients compared to healthy controls or patients with frontotemporal lobe degeneration (FTLD).
  • Quantitative analysis of Aβ burden is essential for comparing patient groups and monitoring therapeutic trials.
  • Novel imaging agents with different half-lives ((11)C and (18)F) enable various image acquisition strategies.

Conclusions:

  • In vivo amyloid PET imaging is a valuable tool for diagnosing and understanding Alzheimer's disease.
  • Quantitative analysis of Aβ burden is critical for clinical applications and therapeutic development.
  • The development of new imaging agents and acquisition methods enhances the assessment of Aβ deposition in the brain.